CDK9 inhibition represents a therapeutically tractable approach for reducing the expression of short‐lived survival factors such as MCL‐1 and subsequently driving apoptosis in tumor cells that depend upon these factors for survival [17, 25, 31]. Here, MCL1 is linked to neoplasm.